For nearly two decades, we’ve assisted pharmaceutical, biotechnology, consumer health, diagnostic, digital health, and medical device organisations in attracting and developing senior executives.
Whether you are a start-up, an established corporation, or a CMO, and working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.
New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.
Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.